Opus Genetics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Opus Genetics, Inc. (IRD) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$9.37 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-03-09
- Opus Genetics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$3.06M, a 165.45% decline year-over-year.
- Opus Genetics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $3.00M.
- Opus Genetics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$10.02M, a 504.38% decline year-over-year.
- Opus Genetics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $710.34K.
- Opus Genetics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$9.37M, a 309.03% decline from fiscal 2016.
- Opus Genetics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $4.48M, a 53.07% decline from fiscal 2015.
- Opus Genetics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $9.55M.
- Opus Genetics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$22.66M, a 2780.12% decline from fiscal 2013.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$66.21K derived: sum of 2 quarters · filed 2018-03-09 | -$10.08M derived: sum of 3 quarters · filed 2018-03-09 | -$9.37M 10-K · filed 2018-03-09 |
| 2017-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | -$7.02M derived: sum of 2 quarters · filed 2017-11-03 | -$6.31M 10-Q · filed 2017-11-03 | -$1.63M derived: sum of 4 quarters · filed 2018-03-09 |
| 2017-06-30 | -$10.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | -$9.31M 10-Q · filed 2017-08-04 | -$4.63M derived: sum of 3 quarters · filed 2018-03-09 | -$6.53M derived: sum of 4 quarters · filed 2018-03-09 |
| 2017-03-31 | $710.34K 10-Q · filed 2017-05-03 | $5.39M derived: sum of 2 quarters · filed 2018-03-09 | $3.48M derived: sum of 3 quarters · filed 2018-03-09 | $5.96M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-12-31 | $4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $2.77M derived: sum of 2 quarters · filed 2018-03-09 | $5.25M derived: sum of 3 quarters · filed 2018-03-09 | $4.48M 10-K · filed 2018-03-09 |
| 2016-09-30 | -$1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $570.67K derived: sum of 2 quarters · filed 2017-11-03 | -$195.69K 10-Q · filed 2017-11-03 | -$4.47M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $1.71M 10-Q · filed 2017-08-04 | -$2.57M derived: sum of 3 quarters · filed 2018-03-09 | $4.39M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-03-31 | -$766.36K 10-Q · filed 2017-05-03 | -$5.04M derived: sum of 2 quarters · filed 2018-03-09 | $1.92M derived: sum of 3 quarters · filed 2018-03-09 | $4.55M derived: sum of 4 quarters · filed 2018-03-09 |
| 2015-12-31 | -$4.28M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $2.68M derived: sum of 2 quarters · filed 2018-03-09 | $5.32M derived: sum of 3 quarters · filed 2018-03-09 | $9.55M 10-K · filed 2018-03-09 |
| 2015-09-30 | $6.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $9.60M derived: sum of 2 quarters · filed 2016-11-04 | $13.83M 10-Q · filed 2016-11-04 | $11.60M derived: sum of 4 quarters · filed 2017-02-24 |
| 2015-06-30 | $2.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $6.87M 10-Q · filed 2016-08-05 | $4.64M derived: sum of 3 quarters · filed 2017-02-24 | -$15.89M derived: sum of 4 quarters · filed 2017-02-24 |
| 2015-03-31 | $4.24M 10-Q · filed 2016-05-06 | $2.00M derived: sum of 2 quarters · filed 2017-02-24 | -$18.53M derived: sum of 3 quarters · filed 2017-02-24 | -$18.45M derived: sum of 4 quarters · filed 2017-02-24 |
| 2014-12-31 | -$2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | -$22.76M derived: sum of 2 quarters · filed 2017-02-24 | -$22.69M derived: sum of 3 quarters · filed 2017-02-24 | -$22.66M 10-K · filed 2017-02-24 |
| 2014-09-30 | -$20.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | -$20.46M derived: sum of 2 quarters · filed 2015-11-02 | -$20.43M 10-Q · filed 2015-11-02 | -$20.12M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | $74.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $103.76K 10-Q · filed 2015-08-07 | $413.12K derived: sum of 3 quarters · filed 2016-03-14 | |
| 2014-03-31 | $28.83K 10-Q · filed 2015-05-08 | $338.19K derived: sum of 2 quarters · filed 2016-03-14 | ||
| 2013-12-31 | $309.36K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $845.52K 10-K · filed 2016-03-14 | ||
| 2013-09-30 | $536.16K 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |